Anaplastic large cell lymphoma treated with a leukemia-like therapy - Report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol
| Autor: | Roberta Burnelli, Angelo Rosolen, Katia Tettoni, Alberto Garaventa, Luigi Zanesco, Paolo Tamaro, Margherita Comis, Marta Pillon, Simone Cesaro, Maria Giuliano, Emanuele S. G. d'Amore, Maria Luisa Moleti, Gianluca Visintin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2005 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Vincristine Adolescent chemotherapy anaplastic non hodgkin lymphoma pediatric chemotherapy Disease-Free Survival Childhood Anaplastic Large Cell Lymphoma Prednisone hemic and lymphatic diseases Internal medicine Multicenter trial Antineoplastic Combined Chemotherapy Protocols Medicine anaplastic non hodgkin lymphoma Humans Child Anaplastic large-cell lymphoma Cyclophosphamide Survival analysis Neoplasm Staging Outcome Hematology Leukemia business.industry Daunorubicin LSA2-L2 medicine.disease Immunohistochemistry Survival Analysis Clinical trial pediatric Methotrexate Treatment Outcome anaplastic large cell lymphoma Child Preschool Therapy Female Lymphoma Large B-Cell Diffuse business medicine.drug |
| Popis: | BACKGROUND Childhood anaplastic large cell lymphoma (ALCL) is a well defined entity with a rather poor prognosis. Different approaches have been adopted in the treatment of ALCL in various cooperative trials, including short high-dose intensive therapy and leukemia-like protocols. In the early 1990s, the Italian Association of Pediatric Hematology and Oncology (AIEOP) initiated a multicenter trial for the treatment of ALCL based on a modified LSA2-L2 protocol. METHODS Thirty-four consecutive eligible children with newly diagnosed ALCL were enrolled in the AIEOP LNH-92 protocol. Treatment was comprised of an induction of remission phase, followed by consolidation and maintenance for a total duration of 24 months, independently of disease stage. RESULTS Thirty of 34 patients (88%) achieved complete disease remission and 8 patients experienced disease recurrence. With a median follow-up of 8.4 years, the probabilities of survival and event-free survival were 85% (range, 79–91%) and 65% (range, 57–73%), respectively. Therapy was well tolerated and hematologic toxicity was the most frequent toxicity. CONCLUSIONS The leukemia-like protocol AIEOP LNH-92 was found to be an effective treatment for childhood ALCL. Its long duration may be beneficial to specific patient subgroups, but optimal treatment duration in ALCL remains to be elucidated. Cancer 2005. © 2005 American Cancer Society. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|